Group 1 - Eulin Bio submitted an application for H-share listing on the Hong Kong Stock Exchange, marking a significant step towards capitalizing and internationalizing the company [1] - The listing aligns with the current trend of pharmaceutical companies going public in Hong Kong, which may enhance A-share valuation elasticity in the short term and inject capital for R&D and global expansion in the long term [1] Group 2 - Alibaba Health reported a total revenue of 16.697 billion yuan, a year-on-year increase of 17.0%, and a net profit of 1.266 billion yuan, up 64.7% [2] - The core growth driver for Alibaba Health is attributed to the increase in self-operated business revenue, which reached 14.380 billion yuan, growing by 18.6% year-on-year [2] Group 3 - Eucan Vision Bio's OT-702, a biosimilar to EYLEA, received approval from the National Medical Products Administration for treating adult patients with neovascular age-related macular degeneration and diabetic macular edema [3] - The approval provides more treatment options for patients in China and is expected to boost the company's stock price in the short term while supporting long-term valuation [3] Group 4 - Roche has initiated a response plan to increase production and supply of its flu treatment, Tamiflu, to the Chinese market amid rising demand during the flu season [4] - This response highlights the importance of the Chinese market and the ongoing supply-demand imbalance for flu treatments [4] Group 5 - Boya Bio received a drug registration certificate for Tetanus Human Immunoglobulin from the National Medical Products Administration, adding to its product pipeline [5] - The approval is expected to enhance the company's R&D enthusiasm, although it is not anticipated to significantly impact the company's operating performance in 2025 [5]

Core Viewpoint - The article discusses a groundbreaking research study that introduces a long-lasting CAR-T cell platform for the delivery of biologics, specifically targeting chronic diseases like obesity and diabetes, offering a potential solution for patients requiring lifelong treatment [7][8][20]. Group 1: Research Breakthroughs - The research team from Tsinghua University developed a revolutionary long-lived CAR-T cell, named GD2TIF, which can achieve sustained release of GLP-1, a key drug for obesity and diabetes, with a single injection [8][18]. - This innovative approach allows for long-term management of chronic diseases, potentially eliminating the need for repeated injections that are common with current peptide/protein biologics [7][20]. Group 2: Mechanism and Advantages - The GD2TIF cells can maintain stable levels in the body without the need for chemotherapy pre-treatment, which is often risky for non-cancer patients [16][17]. - The platform targets GD2, a tumor-associated antigen, ensuring safety by minimizing off-target effects, as GD2 is highly expressed in certain tumors but not in normal tissues [16][17]. Group 3: Clinical Implications - In animal models, a single infusion of GD2TIF cells secreting GLP-1 resulted in sustained weight management and normal blood sugar levels, meeting clinical "cure" standards for obesity and diabetes [18][20]. - The research indicates that this method could provide a cost-effective alternative to traditional biologic therapies, which often require ongoing treatment and frequent medical visits [20].